Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Gross Profit (2020 - 2025)

Cytek Biosciences' Gross Profit history spans 6 years, with the latest figure at $32.9 million for Q4 2025.

  • For Q4 2025, Gross Profit fell 2.28% year-over-year to $32.9 million; the TTM value through Dec 2025 reached $104.5 million, down 5.98%, while the annual FY2025 figure was $104.5 million, 5.98% down from the prior year.
  • Gross Profit reached $32.9 million in Q4 2025 per CTKB's latest filing, up from $27.6 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $33.7 million in Q4 2024 to a low of $14.5 million in Q1 2021.
  • Average Gross Profit over 5 years is $25.3 million, with a median of $25.0 million recorded in 2022.
  • Peak YoY movement for Gross Profit: skyrocketed 138.75% in 2021, then fell 12.41% in 2025.
  • A 5-year view of Gross Profit shows it stood at $23.6 million in 2021, then increased by 24.28% to $29.4 million in 2022, then increased by 12.51% to $33.0 million in 2023, then rose by 1.83% to $33.7 million in 2024, then fell by 2.28% to $32.9 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Gross Profit are $32.9 million (Q4 2025), $27.6 million (Q3 2025), and $23.9 million (Q2 2025).